CGinBites signs exclusive Acellex 2 mg supply deal in Thailand worth KRW 9.19 bn
CGinBites has entered an exclusive supply and sales agreement with Biopharm Chemicals for Acellex 2 mg in Thailand.
How this call is verified
The ▲ Bullish call is auto-verified against the actual KOSPI price in ~12h.
Bar: KOSPI ±0.9% within 24h · every verdict lands on the public ledger
AI comment — why bullish
The exclusive Acellex 2 mg supply contract in Thailand could lift CG인바이츠’s near‑term revenue outlook. At a contract value of KRW 9.19 bn, the deal represents roughly 30 % of the company’s most recent revenue, indicating a material contribution. Granting exclusive sales rights may also open a foothold for future growth in the Thai market. However, the filing does not disclose profit margins or cost structure, so the net earnings impact remains uncertain. Assuming execution proceeds as planned, the market is likely to price in a positive earnings revision within the next day.
Market data
CG인바이츠 · 083790 · KOSDAQ →Previous-close data, updated T+1 · Source: Financial Services Commission of Korea via data.go.kr
Key takeaway
"CGinBites signs exclusive Acellex 2 mg supply deal in Thailand worth KRW 9.19 bn" — BullBear's AI rates this story as a bullish (positive) signal for markets, with a market-impact score of 70 out of 100. That score reflects how strongly the story is likely to move Bitcoin, US equities, the dollar, and gold, and near-duplicate coverage of the same event is clustered so only the representative article is scored. Reported by 금융감독원 전자공시(DART) on September 07, 2026. The call is verified against the actual 24-hour price move on BullBear's public conviction ledger.
Catch the next bull catalyst
Telegram alerts when our AI scores a story 80+/100 impact (~1-3 per day, no spam). Verified 30d hit rate 43.0%.